Jenny Jaeeun Ko1, Alexander C Klimowicz2, Amanda Jagdis3, Tien Phan4, Janessa Laskin5, Harold Y Lau4, Jodi E Siever6, Stephanie K Petrillo2, Thomas A Thomson7, M Sarah Rose8, Gwyn Bebb1, Anthony M Magliocco9, Desirée Hao1. 1. Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. 2. Functional Tissue Imaging Unit, Translational Research Laboratory, University of Calgary, Calgary, Alberta, Canada. 3. Department of Allergy and Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Department of Radiation Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. 5. Department of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada. 6. Department of Biostatistics, Public Health Innovation & Decision Support Population and Public Health, Alberta Health Services, Alberta, Canada. 7. Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 8. Department of Biostatistics, Research Facilitation, Alberta Health Services, Alberta, Canada. 9. Department of Anatomic Pathology, Esoteric Laboratory Services, H. Lee Moffitt Cancer Center, Tampa, Florida.
Abstract
BACKGROUND: In advanced nasopharyngeal carcinoma (NPC), biomarkers may help predict survival. METHODS: Tumoral expression of ataxia-telangiectasia mutated (ATM), thymidylate synthetase (THMS), and ribonucleotide reductase subunit M1 (RRM1), was correlated with survival in patients with nonmetastatic NPC using quantitative fluorescence immunohistochemistry with automated quantitative digital image analysis. RESULTS: Of the 146 patients included, 58 patients (40%) received concurrent chemoradiation therapy; the remainder was treated with radiation. Overall survival (OS) at 5 years was 71% (95% confidence interval [CI], 62% to 78%); disease-free survival (DFS) was 48% (95% CI, 39% to 57%). OS worsened for increasing values of ATM (hazard ratio [HR], 2.83; 95% CI, 1.01-7.94; p = .049) for values greater than the 75th percentile compared to less than the 25th percentile, but improved for tumors with higher THMS levels (HR, 0.44; 95% CI, 0.20-0.94; p = .033) for values greater than the 25th percentile compared to less than or equal to the 25th percentile. RRM1 was not associated with OS (p = .748). No biomarkers were associated with DFS. CONCLUSION: In our cohort, relative overexpression of ATM and low THMS levels were associated with worse OS.
BACKGROUND: In advanced nasopharyngeal carcinoma (NPC), biomarkers may help predict survival. METHODS: Tumoral expression of ataxia-telangiectasia mutated (ATM), thymidylate synthetase (THMS), and ribonucleotide reductase subunit M1 (RRM1), was correlated with survival in patients with nonmetastatic NPC using quantitative fluorescence immunohistochemistry with automated quantitative digital image analysis. RESULTS: Of the 146 patients included, 58 patients (40%) received concurrent chemoradiation therapy; the remainder was treated with radiation. Overall survival (OS) at 5 years was 71% (95% confidence interval [CI], 62% to 78%); disease-free survival (DFS) was 48% (95% CI, 39% to 57%). OS worsened for increasing values of ATM (hazard ratio [HR], 2.83; 95% CI, 1.01-7.94; p = .049) for values greater than the 75th percentile compared to less than the 25th percentile, but improved for tumors with higher THMS levels (HR, 0.44; 95% CI, 0.20-0.94; p = .033) for values greater than the 25th percentile compared to less than or equal to the 25th percentile. RRM1 was not associated with OS (p = .748). No biomarkers were associated with DFS. CONCLUSION: In our cohort, relative overexpression of ATM and low THMS levels were associated with worse OS.
Authors: Christina A Wicker; Vinita Takiar; Rangaswamy Suganya; Susanne M Arnold; Yolanda M Brill; Li Chen; Craig M Horbinski; Dana Napier; Joseph Valentino; Mahesh R Kudrimoti; Guoqiang Yu; Tadahide Izumi Journal: Oral Oncol Date: 2020-08-12 Impact factor: 5.337
Authors: Christianne Hoey; Jessica Ray; Jouhyun Jeon; Xiaoyong Huang; Samira Taeb; Jarkko Ylanko; David W Andrews; Paul C Boutros; Stanley K Liu Journal: Mol Oncol Date: 2018-06-14 Impact factor: 6.603